Intra-Cellular Therapies Inc. (ITCI) financial statements (2021 and earlier)

Company profile

Business Address 430 EAST 29TH STREET
NEW YORK, NY 10016
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
3/31/2020
Q1
12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments6030112918010810292
Cash and cash equivalents6030112918010810292
Restricted cash and investments1111   
Receivables11721   
Inventory, net of allowances, customer advances and progress billings7321   
Inventory7321   
Other undisclosed current assets612432283277123157197
Total current assets:691745419461230259288
Noncurrent Assets
Operating lease, right-of-use asset242420181819 
Property, plant and equipment2222222
Other noncurrent assets0000000
Deferred tax assets, net1
Other undisclosed noncurrent assets    0019
Total noncurrent assets:26262220212122
TOTAL ASSETS:717771441481251281310
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities20211717231411
Accounts payable69511766
Employee-related liabilities15121161586
Debt   335 
Other undisclosed current liabilities16172311101521
Total current liabilities:37384031363333
Noncurrent Liabilities
Long-term debt and lease obligation242421202020 
Operating lease, liability242421202020 
Other undisclosed noncurrent liabilities(24)(24)(21)   21
Total noncurrent liabilities: 242120202021
Total liabilities:60626151565453
Stockholders' equity
Stockholders' equity attributable to parent657709380430195227257
Common stock0000000
Additional paid in capital1,5931,5851,2001,188905896891
Accumulated other comprehensive income (loss)011(0)000
Accumulated deficit(937)(876)(821)(758)(710)(670)(635)
Total stockholders' equity:657709380430195227257
TOTAL LIABILITIES AND EQUITY:717771441481251281310

Income statement (P&L) ($ in millions)

12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
3/31/2020
Q1
12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
Revenues127210  
Cost of revenue
(Cost of Goods and Services Sold)
   (0)   
Gross profit:12721   
Operating expenses(74)(63)(67)(50)(42)(36)(39)
Other undisclosed operating income   00  
Operating loss:(61)(56)(65)(49)(42)(36)(39)
Nonoperating income
(Investment Income, Nonoperating)
1112122
Loss from continuing operations before income taxes:(61)(55)(64)(47)(41)(35)(37)
Income tax expense(0)  (0)  (0)
Net loss available to common stockholders, diluted:(61)(55)(64)(47)(41)(35)(37)

Comprehensive Income ($ in millions)

12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
3/31/2020
Q1
12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
Net loss:(61)(55)(64)(47)(41)(35)(37)
Other comprehensive income (loss)(0)(0)1(0)(0)(0)0
Comprehensive loss, net of tax, attributable to parent:(61)(56)(62)(48)(41)(35)(37)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: